A preclinical precision medicine biotech company, looking to leverage their genome editing platform technology, was seeking support in narrowing their indication focus. To justify the R&D investment into an initial indication, the company needed a comprehensive commercial analysis of 10 potential indications. Kineticos was also asked to provide a valuation that could be leveraged throughout the fund raising process.


For each indication, Kineticos performed a commercial assessment that included the below components.

  • Disease and treatment overview
  • Competitive landscape
  • Target Product Profiles including minimum market entry and gold standard for:
    • Safety
    • Efficacy
    • Dosing
    • Health Economics
  • 5-year revenue forecasts


The 10 indication summaries were leveraged to calculate a data-driven company valuation and determine a lead indication, of which both were leveraged in seed round and series A investor meetings.